中华风湿病学杂志
中華風濕病學雜誌
중화풍습병학잡지
CHINESE JOURNAL OF RHEUMATOLOGY
2011年
3期
179-182
,共4页
姚中强%马军%刘湘源%王国峰%于孟学
姚中彊%馬軍%劉湘源%王國峰%于孟學
요중강%마군%류상원%왕국봉%우맹학
核蛋白类%酶联免疫吸附测定%高血压,肺性%Logistic模型
覈蛋白類%酶聯免疫吸附測定%高血壓,肺性%Logistic模型
핵단백류%매련면역흡부측정%고혈압,폐성%Logistic모형
Nucleoproteins%Enzyme-linked immunosorbent assay%Hypertension,pulmonary%Logistic models
目的 探讨抗核仁蛋白 B23抗体在系统性硬化病(SSc)患者中的临床意义.方法 采用酶联免疫吸附试验(ELISA)法检测SSc患者血清中抗核仁蛋白B23抗体,非参数检验比较抗核仁蛋白B23抗体阳性组和阴性组之间临床表现和免疫指标的差异,使用Logistic回归分析抗核仁蛋白B23抗体与患者临床表现、免疫指标的相关性.结果 纳入156例SSc患者,其中抗核仁蛋白B23抗体36例阳性,占23.1%.非参数检验表明,抗核仁蛋白B23抗体阳性组的用力肺活量(FVC)、肺一氧化碳弥散功能(DLco)明显低于B23抗体阴性组;肺动脉高压发生率更高,抗着丝点抗体、抗U1RNP抗体和抗核仁纤维蛋白抗体阳性率更高.多因素Logistic回归分析表明,抗核仁蛋白B23抗体阳性是SSc患者发生肺动脉高压的独立危险因素(OR=123.92,95%CI 26.67～575.66,P＜0.01),是严重胃肠道受累的保护性因素(OR=0.08,95%CI 0.01～0.70,P＜0.05).Logistic回归分析表明,抗核仁蛋白B23抗体与抗核仁纤维蛋白抗体(OR=11.50,95%CI 3.85～34.37,P＜0.O1)、抗U1RNP抗体相关(OR=3.43,95%CI 1.01～11.63,P＜0.05),与不同程度肺动脉高压均显著相关.结论 抗核仁蛋白B23抗体阳性患者应该严密监测其肺动脉压力.
目的 探討抗覈仁蛋白 B23抗體在繫統性硬化病(SSc)患者中的臨床意義.方法 採用酶聯免疫吸附試驗(ELISA)法檢測SSc患者血清中抗覈仁蛋白B23抗體,非參數檢驗比較抗覈仁蛋白B23抗體暘性組和陰性組之間臨床錶現和免疫指標的差異,使用Logistic迴歸分析抗覈仁蛋白B23抗體與患者臨床錶現、免疫指標的相關性.結果 納入156例SSc患者,其中抗覈仁蛋白B23抗體36例暘性,佔23.1%.非參數檢驗錶明,抗覈仁蛋白B23抗體暘性組的用力肺活量(FVC)、肺一氧化碳瀰散功能(DLco)明顯低于B23抗體陰性組;肺動脈高壓髮生率更高,抗著絲點抗體、抗U1RNP抗體和抗覈仁纖維蛋白抗體暘性率更高.多因素Logistic迴歸分析錶明,抗覈仁蛋白B23抗體暘性是SSc患者髮生肺動脈高壓的獨立危險因素(OR=123.92,95%CI 26.67～575.66,P＜0.01),是嚴重胃腸道受纍的保護性因素(OR=0.08,95%CI 0.01～0.70,P＜0.05).Logistic迴歸分析錶明,抗覈仁蛋白B23抗體與抗覈仁纖維蛋白抗體(OR=11.50,95%CI 3.85～34.37,P＜0.O1)、抗U1RNP抗體相關(OR=3.43,95%CI 1.01～11.63,P＜0.05),與不同程度肺動脈高壓均顯著相關.結論 抗覈仁蛋白B23抗體暘性患者應該嚴密鑑測其肺動脈壓力.
목적 탐토항핵인단백 B23항체재계통성경화병(SSc)환자중적림상의의.방법 채용매련면역흡부시험(ELISA)법검측SSc환자혈청중항핵인단백B23항체,비삼수검험비교항핵인단백B23항체양성조화음성조지간림상표현화면역지표적차이,사용Logistic회귀분석항핵인단백B23항체여환자림상표현、면역지표적상관성.결과 납입156례SSc환자,기중항핵인단백B23항체36례양성,점23.1%.비삼수검험표명,항핵인단백B23항체양성조적용력폐활량(FVC)、폐일양화탄미산공능(DLco)명현저우B23항체음성조;폐동맥고압발생솔경고,항착사점항체、항U1RNP항체화항핵인섬유단백항체양성솔경고.다인소Logistic회귀분석표명,항핵인단백B23항체양성시SSc환자발생폐동맥고압적독립위험인소(OR=123.92,95%CI 26.67～575.66,P＜0.01),시엄중위장도수루적보호성인소(OR=0.08,95%CI 0.01～0.70,P＜0.05).Logistic회귀분석표명,항핵인단백B23항체여항핵인섬유단백항체(OR=11.50,95%CI 3.85～34.37,P＜0.O1)、항U1RNP항체상관(OR=3.43,95%CI 1.01～11.63,P＜0.05),여불동정도폐동맥고압균현저상관.결론 항핵인단백B23항체양성환자응해엄밀감측기폐동맥압력.
Objective To explore the clinical significance of anti-nuclear protein B23 antibody in systemic sclerosis. Methods Enzyme-linked immunosorbent assay was employed to detect the serum antinuclear B23 autoantibody. Mann-Whitney U test was used to compare the clinical and autoantibody profiles between SSc patients with B23 antibody and those without B23 antibody. Logistic regression analysis was employed to analyze the correlation between B23 antibody and clinical manifestations and autoantibody profiles. Results Mann-Whitney U test showed that, forced vital capacity (FVC) diffusion capacity of CO (DLco) in B23 positive SSc was significantly lower than that in B23 negative counterparts, pulmonary artery hypertension was more prevalent in B23 positive SSc patients. While anti-fibrillarin, anti-U1RNP, and antic entromere antibodies were more prevalent in B23 positive SSc. Multivariate logistic regression showed that anti-B23 antibody positivity was an independent risk factor for pulmonary artery hypertension in SSc (OR=123.92, 95％CI 26.67～575.66, P＜0.01), and a protective factor for severe gastrointestinal involvement (OR=0.08, 95％CI 0.01 ～0.70, P＜O.05). Logistic analysis showed that anti-B23 antibody was correlated with antifibrillarin (OR=11.50, 95％CI3.85～34.37, P＜0.01) and anti-U1RNP antibodies (OR=3.43, 95％CI 1.01～11.63, P＜0.05), and correlated with different degree of pulmonary artery hypertension. Conclusion The pulmonary artery pressure should be monitored closely in those SSc patients with a positive B23 antibody.
